Skip to main content
2023 Midyear Clinical Meeting & Exhibition Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Presentation Icons
Certfified Pharmacy Executive Leader (CPEL)
Certfified Pharmacy Executive Leader (CPEL)
Integrated Informatics Institute
Integrated Informatics Institute
Back
Handout

Educational Sessions

Another Great Debate — Semaglutide versus Tirzepatide for Type 2 Diabetes and Obesity

Monday, December 4, 2023
4:00 PM – 5:15 PM  
Location: ACC, Room 303b, Level 3
CE Credits 1.25 contact hours
Planned in cooperation with the ASHP Section of Ambulatory Care Practitioners
Activity #: 0204-0000-23-249-L01-P
Activity Type: Application-based
Target Audience: Pharmacist

Learning Objectives:

  • Summarize treatment recommendations for type 2 diabetes and obesity from the American Diabetes Association Standards of Care.
  • Given a case scenario, assess the benefits, risks, and barriers of semaglutide for type 2 diabetes and obesity.
  • Given a case scenario, evaluate the benefits, risks, and barriers of tirzepatide for type 2 diabetes and obesity.